IP Verse

Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating Cancer

Patent No. EP2651442 (titled "Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating Cancer") was filed by University OF Maryland on Dec 14, 2011. The application was issued on Apr 22, 2020.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANJan 21, 2021POTTER CLARKSON
GEMOAB MONOCLONALS GMBHJan 20, 2021KAILUWEIT & UHLEMANN
AVENCELL EUROPE GMBHJan 20, 2021KAILUWEIT & UHLEMANN PATENTANWALTE PARTNERSCHAFT MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

EP2651442

UNIVERSITY OF MARYLAND
Application Number
EP11849221A
Filing Date
Dec 14, 2011
Status
Revoked
Dec 13, 2025
Publication Date
Apr 22, 2020
External Links
Slate, Register , Google Patents